focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.42
Bid: 2.33
Ask: 2.48
Change: 0.155 (6.89%)
Spread: 0.15 (6.438%)
Open: 2.26
High: 2.48
Low: 2.26
Prev. Close: 2.25
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

Fri, 30th Jul 2021 15:34

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News:

----------

Berkeley Group Holdings PLC - Cobham, England-based housebuilder - Non-Executive Director Alison Nimmo will step down from board at September 3 annual general meeting, having served for 10 years. Nimmo joined the board of St Modwen Properties PLC back in February. She was chief executive of the Crown Estate from 2012 to 2019. The Crown Estate, which manages the Queen's property holdings, is the largest property owner in London's West End. She also held senior roles organising the London 2012 Olympic Games.

----------

ImmuPharma PLC - London-based developer of peptide-based therapeutics for autoimmune diseases - Chief Executive Officer Dimitri Dimitriou steps down immediately "in order to pursue a number of other external opportunities". Chair Tim McCarthy takes over as CEO. ImmuPharma will look for a non-executive chair, and McCarthy will remain chair until it finds one. At the same time, Senior Non-Executive Director Franco di Muzio and Non-Executive Director Stephane Mery also will step down. To replace them, ImmuPharma says it has found new non-executive directors "with direct experience in building a more diverse drug development business together with current public market experience". Sanjeev Pandya is hired as senior independent non-executive director. Pandya was CEO of AIM-listed Advanced Oncotherapy PLC and head of Europe Regulatory & Medical at Reckitt Benckiser Group PLC. Also hires Lisa Baderoon as non-executive director. Baderoon was a partner at financial public-relations firm Buchanan Communications and has been advising ImmuPharma since its AIM float in 2006. It is looking to hire one more non-executive director.

----------

Sylvania Platinum Ltd - South Africa-focused platinum group metals producer - Hires Adrian Reynolds as independent non-executive director, starting on Sunday. Reynolds has more than 40 years' experience in mining and minerals, Sylvania notes, and currently is a director of Resolute Mining Ltd and Mkango Resources Ltd, both London listings.

----------

FD Technologies PLC - Newry, County Down-based financial markets technology, formerly known as First Derivatives - Steve Fisher resigns as non-executive director and will step down at the end of January 2022. Fisher has been appointed to a full-time senior executive role at Salesforce.com Inc, where he previously had worked, FD Technologies explains. The search for a replacement non-executive director has begun.

----------

Record PLC - Windsor, Berkshire-based currency and derivatives manager - Hires Matt Hotson as independent non-executive director, starting Friday. Hotson has worked at Arrow Global Group PLC, RSA Insurance Group PLC, Cable & Wireless Worldwide PLC, and Legal & General Group PLC over a 25-year career.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2016 08:47

ImmuPharma completes patient recruitment in Lupuzor trial

(ShareCast News) - Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor. The AIM-traded firm described Lupuzor as its lead programme for the p

Read more
16 Nov 2016 10:41

ImmuPharma Says Paper Detailing IPP-204106 Mechanism Published

Read more
14 Sep 2016 16:47

ImmuPharma makes positive progress in Lupuzor trials

(ShareCast News) - Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of Lupuzor - its lead programme for the potential breakthrough compound for Lupus - on Wednesday. The AIM-traded firm said it now had a total of 11 sites

Read more
14 Sep 2016 08:45

ImmuPharma Makes Progress With Lupuzor Phase III Trial

Read more
7 Jun 2016 06:59

ImmuPharma Begins Dosing Of European Patients In Lupuzor Trial

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
4 May 2016 09:17

ImmuPharma 2015 Loss Widens As It Focuses On Lupuzor Development

Read more
27 Apr 2016 15:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Mar 2016 10:27

ImmuPharma Begins Patient Recruitment In Europe For Lupuzor Trial

Read more
15 Feb 2016 15:32

ImmuPharma doses first patients in the US

(ShareCast News) - ImmuPharma's clinical expansion into the US reached a significant point on Monday, with the first dosing of patients in its Phase III trial of the in-development lupus treatment Lupuzor. The AIM-traded drug discovery and development company confirmed in a statement that dosing had

Read more
15 Feb 2016 09:02

ImmuPharma Hopeful As US Patients Begin Dosing In Lupus Clinical Trial

Read more
5 Feb 2016 15:26

ImmuPharma to raise £7.5m for 'blockbuster' drug

(ShareCast News) - The 'blockbuster' potential of a drug in development saw ImmuPharma proposing a £7.5m fund raise on Friday. The AIM-traded specialist drug discovery and development company said the deal included a proposed conditional non-preemptive placing of no less than 11,824,877 Placing Shar

Read more
5 Feb 2016 10:32

WINNERS & LOSERS SUMMARY: Just Eat Leaps As It Gobbles Up Takeaways

Read more
5 Feb 2016 08:34

ImmuPharma Looks To Raise Minimum GBP7.5 Million In Equity (ALLISS)

Read more
7 Dec 2015 09:36

ImmuPharma Says US Sites Open For Lupuzor Phase III Trial Recruitment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.